Tuesday, September 2, 2014

Fwd: CDER New September 2, 2014



---------- Forwarded message ----------
From: U.S. Food & Drug Administration (FDA) <fda@service.govdelivery.com>
Date: Tue, Sep 2, 2014 at 8:55 AM
Subject: CDER New September 2, 2014
To: iammejtm@gmail.com


FDA (U.S. Food and Drug Administration)

What's New on the FDA Drugs Site

August 29, 2014


New and Generic Drug Approvals

August 28, 2014

Drug NameActive Ingredient Dosage Form/RouteSponsor Submission Type
Aleve Pm diphenhydramine hydrochloride; naproxen sodium Tablet;Oral Bayer Hlthcare Labeling Revision
Avonex interferon beta-1a Vial Biogen Labeling Revision
Decitabine decitabine Injectable;Injection Sandoz Inc Approval
Ella ulipristal acetate Tablet;Oral Lab Hra Pharma Labeling Revision
Frovatriptan Succinate frovatriptan succinate Tablet;Oral Mylan Pharms Inc Approval
Ifex ifosfamide Injectable;Injection Baxter Hlthcare Labeling Revision
Ifex/Mesnex Kit ifosfamide; mesna Injectable;Injection Baxter Hlthcare Labeling Revision
Lamivudine and Zidovudine lamivudine;zidovudine Tablet;Oral Mylan Pharms Inc Approval
Metformin Hydrochloride metformin hydrochloride Tablet;Oral Zydus Hlthcare Approval
Oxycodone; Acetaminophen oxycodone;acetaminophen Tablet;Oral Rhodes Pharms Approval
Requip ropinirole hydrochloride Tablet;Oral Glaxosmithkline Llc Labeling Revision
Requip Xl ropinirole hydrochloride Tablet, Extended Release;Oral Glaxosmithkline Llc Labeling Revision
Rimso-50 dimethyl sulfoxide Solution;Intravesical Mylan Institutional Manufacturing Change or Addition
Stavzor valproic acid Capsule, Delayed Release;Oral Banner Pharmacaps Labeling Revision
Stribild cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate Tablet;Oral Gilead Sciences Inc Efficacy Supplement with Clinical Data to Support

 


FDA Logo

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:
Visit Us on Facebook Visit Us on Twitter Visit Us on YouTube Sign up for email updates Visit Us on Flickr Visit Our Blog  

This email was sent to iammejtm@gmail.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery



--
Jeremy Tobias Matthews

No comments:

Post a Comment